While the steroidal mineralocorticoid receptor antagonists (MRA) spironolactone and eplerenone have demonstrated mortality benefit for patients with HFrEF [[54], [55], [56]], the nonsteroidal MRA (nsMRA) finerenone was evaluated for the purposes of reducing adverse kidney outcomes in patients with T2DM, demonstrating significant cardiovascular benefits. Here, NR3C2 is linked to type 2 diabetes mellitus.